Patent intelligence · US
US 6773719
Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
Patent details — US 6773719
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 10, 2004
- Expiration
- Aug 5, 2024
- Applicant
- Esperion LUV Development, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K31/685, A61K9/0019, A61K9/127
Quick answer
US 6773719 (Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias) is held by Esperion LUV Development, Inc.. Status: expired. Granted Aug 10, 2004. Expires Aug 5, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Esperion LUV Development, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/685, A61K9/0019, A61K9/127
More from Esperion LUV Development, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12404227
Methods of making bempedoic acid and compositions of the same
granted -
US 12398087
Methods of making bempedoic acid and compositions of the same
granted -
US 12344578
Salt forms of bempedoic acid and methods for using the same
granted -
US 11987548
Methods of making bempedoic acid and compositions of the same
granted -
US 11926584
Methods of making bempedoic acid and compositions of the same
granted -
US 11760714
Methods of making bempedoic acid and compositions of the same
granted -
US 11744816
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
granted -
US 11613511
Methods of making bempedoic acid and compositions of the same
granted
Frequently asked questions
What is US patent 6773719?
US 6773719 (Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias) is held by Esperion LUV Development, Inc.. Status: expired. Granted Aug 10, 2004. Expires Aug 5, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6773719?
Esperion LUV Development, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 55 pharmaceutical patents for this assignee.
When does US 6773719 expire?
Our index shows an expiration date of Aug 5, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.